Comment

• "Influences of cigarette smoking and Helicobacter pylori infection on the development of gastric cancer" - Yutaka Kiyohara,  Department of Environmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka,  Japan
   
  "We assessed the separate and joint influences of cigarette smoking and Helicobacter pylori infection on the development of gastric cancer in a population-based prospective study of Japanese men. The multivariate-adjusted risk of gastric cancer  was significantly higher in current smokers than in current nonsmokers. The risk of gastric cancer increased steeply for men who had both a smoking habit and Helicobacter pylori infection compared with those who did not have both risk factors. If causal, the estimated population attributable fraction of gastric cancer for cigarette smoking was approximately half that for Helicobacter pylori infection (28.4% vs. 56.2%). The findings of our paper suggest that cigarette smoking and Helicobacter pylori infection are importantt risk factors for gastric cancer in Japanese men. The magnitude of their combined influence is considerable"
  (Comment on: Shikata K et al.: "Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence: the Hisayama Study", Am J Epidemiol. 2008 Dec 15;168(12):1409-15)

Press Releases

• "Research Shows Cell's Inactive State is Critical for Effectiveness of Cancer Treatment" - Memorial Sloan-Kettering Cancer Center, New York, USA - www.mskcc.org

Literature Selection

• Naucler P et al.: "Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening", J Natl Cancer Inst. 2009 Jan 13. [Epub ahead of print]
• Paramsothy P et al.."The Effect of Highly Active Antiretroviral Therapy on Human Papillomavirus Clearance and Cervical Cytology", Obstet Gynecol. 2009 Jan;113(1):26-31
• Markovitch O et al.: "Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients", Breast Cancer Res Treat. 2009 Jan;113(2):301-6

Comment

• "Reduced risk in colorectal cancer associated with menopausal hormone therapy " - Jill R. Johnson, Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota; USA
   
  "We evaluated colorectal cancer risk associated with duration and recency of menopausal hormone therapy use. In our study, we abstracted data from 56,733 postmenopausal women who participated in the Breast Cancer Detection Demonstration Project follow-up study.  During an average 15 years of follow-up, we identified 960 new cases of colorectal cancer in this population. We found that ever use of any menopausal hormone therapy was associated with a reduced risk of colorectal cancer. Any use of estrogen therapy was associated with a 17 percent reduced risk in colorectal cancer. Among those who used estrogen, the largest reductions were seen among those who were current users (25 percent reduced risk) and users of ten or more years duration (26 percent reduced risk). We also found a 22 percent reduced risk among those who had ever used estrogen plus progestin in combination.  Furthermore, we found a 36 percent reduction in risk among those who had used progestin sequentially, or less than 15 days per month. Past users of estrogen plus progestin, who had stopped at least five years ago, had a 45 percent risk reduction"
  (Comment on: Johnson JR et al.: "Menopausal hormone therapy and risk of colorectal cancer", Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):196-203)